JPWO2020093024A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020093024A5 JPWO2020093024A5 JP2021523009A JP2021523009A JPWO2020093024A5 JP WO2020093024 A5 JPWO2020093024 A5 JP WO2020093024A5 JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP WO2020093024 A5 JPWO2020093024 A5 JP WO2020093024A5
- Authority
- JP
- Japan
- Prior art keywords
- inventions described
- inventions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862754378P | 2018-11-01 | 2018-11-01 | |
US62/754,378 | 2018-11-01 | ||
PCT/US2019/059556 WO2020093024A2 (en) | 2018-11-01 | 2019-11-01 | Methods of administering anti-tim-3 antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022505923A JP2022505923A (ja) | 2022-01-14 |
JPWO2020093024A5 true JPWO2020093024A5 (zh) | 2022-11-08 |
Family
ID=69159932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021523009A Pending JP2022505923A (ja) | 2018-11-01 | 2019-11-01 | 抗tim-3抗体を投与する方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220073616A1 (zh) |
EP (1) | EP3873612A2 (zh) |
JP (1) | JP2022505923A (zh) |
CN (1) | CN113301961A (zh) |
AU (1) | AU2019372436A1 (zh) |
CA (1) | CA3117371A1 (zh) |
IL (1) | IL282708A (zh) |
WO (1) | WO2020093024A2 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018158727A1 (en) | 2017-03-02 | 2018-09-07 | National Research Council Of Canada | Tgf-β-receptor ectodomain fusion molecules and uses thereof |
KR20230028795A (ko) * | 2020-06-26 | 2023-03-02 | 소렌토 쎄라퓨틱스, 인코포레이티드 | 면역조절 융합 단백질을 발현하는 종양용해 단순헤르페스 바이러스 (hsv) |
JP2024514590A (ja) * | 2021-04-13 | 2024-04-02 | メディミューン,エルエルシー | Pd-1及びtim-3を標的化する二重特異性抗体 |
WO2022271917A1 (en) * | 2021-06-24 | 2022-12-29 | Bristol-Myers Squibb Company | Transforming growth factor-beta ligand traps for the treatment of disease |
CN116688115B (zh) * | 2022-03-18 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
CN1330664C (zh) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
WO2007145840A2 (en) * | 2006-06-13 | 2007-12-21 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
CA2791383C (en) | 2010-03-05 | 2022-09-20 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
WO2013006490A2 (en) * | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN113549159A (zh) * | 2014-02-10 | 2021-10-26 | 默克专利有限公司 | 靶向TGFβ抑制 |
EA201790173A1 (ru) * | 2014-07-11 | 2017-06-30 | Генмаб А/С | Антитела, связывающие axl |
BR112017007379A2 (pt) * | 2014-10-14 | 2017-12-19 | Dana Farber Cancer Inst Inc | moléculas de anticorpo para pd-l1 e usos das mesmas |
TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3316902A1 (en) * | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
CN109414500B (zh) * | 2016-06-13 | 2022-02-25 | 奥美药业有限公司 | 治疗和诊断用pd-l1特异性单克隆抗体 |
CA3027495A1 (en) * | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JOP20190013A1 (ar) * | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
EP3535586A4 (en) * | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3) |
EA201990743A1 (ru) * | 2016-11-29 | 2019-11-29 | Антитела, направленные против белка-3, содержащего т-клеточный иммуноглобулин и муцин (tim-3) | |
AU2018264455A1 (en) | 2017-05-12 | 2019-11-14 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
-
2019
- 2019-11-01 AU AU2019372436A patent/AU2019372436A1/en active Pending
- 2019-11-01 WO PCT/US2019/059556 patent/WO2020093024A2/en unknown
- 2019-11-01 CA CA3117371A patent/CA3117371A1/en active Pending
- 2019-11-01 EP EP19835890.5A patent/EP3873612A2/en active Pending
- 2019-11-01 CN CN201980086650.3A patent/CN113301961A/zh active Pending
- 2019-11-01 JP JP2021523009A patent/JP2022505923A/ja active Pending
-
2021
- 2021-04-27 IL IL282708A patent/IL282708A/en unknown
- 2021-04-30 US US17/245,476 patent/US20220073616A1/en active Pending